Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

NCT07087054 is registered in ClinicalTrials.gov with Crinetics Pharmaceuticals Inc. as lead sponsor.

NCT NCT07087054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07087054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors
Lead sponsor
Crinetics Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
November 19, 2025
Completion date
January 31, 2030
Enrollment
141 (estimated)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid, carcinoid intestine tumor, carcinoid syndrome, carcinoid syndrome diarrhea, carcinoid tumor, carcinoid tumor of cecum, carcinoid tumor of ileum, carcinoid tumor of liver, carcinoid tumor of pancreas